Zobrazeno 1 - 10
of 171
pro vyhledávání: ''
Autor:
Lu Xu, Delvys Rodriguez-Abreu, Te Chun Hsia, Mehmet Ali Nahit Sendur, Perran Fulden Yumuk, A. Samkari, Irfan Cicin, Olivier Molinier, Bilal Piperdi, Keynote Investigators, Adrian Langleben, Dae Ho Lee, Balazs Medgyasszay, Francisco Orlandi, Michael Boyer, Ticiana A. Leal, Raffaele Califano, Gregory A. Otterson, Martin Reck, Keunchil Park, Nopadol Soparattanapaisarn
Publikováno v:
Journal of Clinical Oncology. 39:2327-2338
PURPOSE Pembrolizumab monotherapy is standard first-line therapy for metastatic non–small-cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) tumor proportion score (TPS) ≥ 50% without actionable driver mutations. It is not known whet
Autor:
Zhihong Chi, Li Zhou, Bin Lian, Bixia Tang, Hong Yao, Jun Guo, Lu Si, Lili Mao, Chuanliang Cui, Xue Bai, Xuan Wang, Siming Li, Xieqiao Yan, Yan Kong, Xinan Sheng, Jie Dai
Publikováno v:
Journal of Clinical Oncology. 39:881-889
PURPOSE Mucosal melanoma (MM) is a highly vascularized tumor with an extremely poor prognosis. In this randomized, open-label, phase II study, we characterized the efficacy and safety of bevacizumab in combination with carboplatin plus paclitaxel (CP
Autor:
Shengxiang Ren, Lunxu Liu, Shun Xu, Ke-Neng Chen, Weimin Mao, Xiaofei Li, Wen-Zhao Zhong, Rong Yin, Bu-Hai Wang, Jian Li, Qun Wang, Shidong Xu, Cheng Huang, Yi-Long Wu, Haitao Ma, Ping Yu, Songtao Xu, Hong-Hong Yan, Jin-Ji Yang, Qing Zhou, Chun Chen, Si-Yang Liu, Ying Cheng, Fan Yang, Lin Wu, Zhidong Liu, Xue-Ning Yang, Yucheng Wei, Yongyu Liu
Publikováno v:
Journal of Clinical Oncology. 39:713-722
PURPOSE ADJUVANT-CTONG1104 (ClinicalTrials.gov identifier: NCT01405079 ), a randomized phase III trial, showed that adjuvant gefitinib treatment significantly improved disease-free survival (DFS) versus vinorelbine plus cisplatin (VP) in patients wit
Autor:
David S. Hong, Yibing Yan, Heinz-Josef Lenz, Chloe E. Atreya, Scott Kopetz, Christopher H. Lieu, Philip A. Philip, Ganiraju C. Manyam, Richard B. Lanman, Katherine A. Guthrie, Anthony M. Magliocco, Luis A. Diaz, Dipen M. Maru, Shannon McDonough, Stephen E. Wang, Kanwal Pratap Singh Raghav, Howard S. Hochster, Carmen J. Allegra, Alexey V. Sorokin, Van K. Morris
Publikováno v:
J Clin Oncol
PURPOSE BRAF V600E mutations are rarely associated with objective responses to the BRAF inhibitor vemurafenib in patients with metastatic colorectal cancer (CRC). Blockade of BRAF V600E by vemurafenib causes feedback upregulation of EGFR, whose signa
Autor:
Alexander Stein, Annegret Kunitz, Hans-Georg Kopp, Gerlinde Egerer, Bernd Kasper, Xiaofei Liu, Jens-Marcus Chemnitz, Martina Crysandt, Patrick Schöffski, Philipp Ivanyi, Viktor Grünwald, Stephan Richter, Markus K. Schuler, Annika Karch, Lars H. Lindner, Sebastian Bauer, Björn Steffen, Silke Zimmermann
Publikováno v:
Journal of Clinical Oncology. 38:3555-3564
PURPOSE Doxorubicin is a standard of care in patients with advanced, inoperable soft tissue sarcoma (STS). We tested whether pazopanib has efficacy comparable to that of doxorubicin in elderly patients with STS and offers superior tolerability for he
Autor:
Shisheng Tan, Sanjun Cai, Ji Zhu, Zhen Zhang, Yaqun Zhu, Hongyan Zhang, Xin Wang, Chen Zhang, Tao Zhang, Jianhui Jia, Jialin Yang, Xinchen Sun, Hui Zhang, Wei Zhang, F. Xia, Juefeng Wan, Yuanyuan Zhao, Anwen Liu, Junxin Wu, Luying Liu, Juying Zhou, Lijun Shen, Gang Cai
Publikováno v:
Journal of Clinical Oncology
PURPOSE Differentiating the irinotecan dose on the basis of the uridine diphosphate glucuronosyltransferase 1A1 ( UGT1A1) genotype improves the pathologic complete response (pCR) rate. In this study, we further investigated preoperative irinotecan co
Autor:
Musib Siddique, C.E. Tsao, Gelsomina L Borromeo, Gary Cook, Peter R. Ebeling, John F Seymour, Ie-Wen Sim, Rita Hardiman, Christian Papatziamos Hjelle, Michael S Hofman
Publikováno v:
Journal of Clinical Oncology. 38:2971-2980
PURPOSE Medication-related osteonecrosis of the jaw (MRONJ) is an infrequent but morbid and potentially serious condition associated with antiresorptive and antiangiogenic therapies. Although MRONJ can be prevented by optimizing oral health, manageme
Autor:
Claudine Isaacs, Michele R. Hacker, Virginia F. Borges, Deborah Toppmeyer, Paulina B. Lange, Steven J. Isakoff, Eric P. Winer, Nadine Tung, Erica L. Mayer, Paul K. Marcom, Judy Garber, Andrew J. Goss, E Hofstatter, Robert D. Legare, Antonio C. Wolff, Banu Arun, Ian E. Krop, Colby Jenkins, Stuart J. Schnitt
Publikováno v:
J Clin Oncol
PURPOSE Platinum compounds have activity in triple-negative breast cancer (TNBC) in germline BRCA mutation carriers ( BRCA carriers). Limited data exist for estrogen receptor (ER)–positive (+) breast cancer among BRCA carriers. INFORM is a randomiz
Autor:
Rashmi Krishna Murthy, Amelia Zelnak, Giuseppe Curigliano, Carey K. Anders, Elisavet Paplomata, Mafalda Oliveira, Eric P. Winer, Virginia F. Borges, Karen A. Gelmon, Alison Conlin, Xuebei An, Michael DiGiovanna, Sibylle Loibl, Alicia Okines, Sara A. Hurvitz, Ruth O'Regan, Philippe L. Bedard, Andrew M Wardley, Lisa A. Carey, Thomas Bachelot, Jo Al Mayor, David Cameron, A. Jo Chien, Nan Lin, Sherene Loi, Vandana G. Abramson, Suzanne McGoldrick, Erika Hamilton, Volkmar Mueller
Publikováno v:
Journal of Clinical Oncology
Scientia
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 23
Lin, N U, Borges, V, Anders, C, Murthy, R K, Paplomata, E, Hamilton, E, Hurvitz, S, Loi, S, Okines, A, Abramson, V, Bedard, P L, Oliveira, M, Mueller, V, Zelnak, A, Digiovanna, M P, Bachelot, T, Chien, A J, O’regan, R, Wardley, A, Conlin, A, Cameron, D, Carey, L, Curigliano, G, Gelmon, K, Loibl, S, Mayor, J, Mcgoldrick, S, An, X & Winer, E P 2020, ' Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial ', Journal of Clinical Oncology, pp. JCO.20.00775 . https://doi.org/10.1200/JCO.20.00775, https://doi.org/10.1200/JCO.20.00775
BASE-Bielefeld Academic Search Engine
Scientia
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 23
Lin, N U, Borges, V, Anders, C, Murthy, R K, Paplomata, E, Hamilton, E, Hurvitz, S, Loi, S, Okines, A, Abramson, V, Bedard, P L, Oliveira, M, Mueller, V, Zelnak, A, Digiovanna, M P, Bachelot, T, Chien, A J, O’regan, R, Wardley, A, Conlin, A, Cameron, D, Carey, L, Curigliano, G, Gelmon, K, Loibl, S, Mayor, J, Mcgoldrick, S, An, X & Winer, E P 2020, ' Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial ', Journal of Clinical Oncology, pp. JCO.20.00775 . https://doi.org/10.1200/JCO.20.00775, https://doi.org/10.1200/JCO.20.00775
BASE-Bielefeld Academic Search Engine
PURPOSE In the HER2CLIMB study, patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer with brain metastases (BMs) showed statistically significant improvement in progression-free survival (PFS) with tucatinib. We desc
Autor:
Gary I. Cohen, Carrie B. Lee, David R. Minor, Jeffrey A. Sosman, John M. Kirkwood, Zeynep Eroglu, Sandra J. Lee, Howard Streicher, Donald P. Lawrence, Omid Hamid, Laura F. Hutchins, Lawrence E. Flaherty, Henry B. Koon, Teresa M. Petrella, Mark R. Albertini, H. Kluger, F. Stephen Hodi, Uma N. M. Rao, Vernon K. Sondak, Ahmad A. Tarhini, Kari Kendra
Publikováno v:
Journal of Clinical Oncology. 38:567-575
PURPOSE Phase III adjuvant trials have reported significant benefits in both relapse-free survival (RFS) and overall survival (OS) for high-dose interferon alfa (HDI) and ipilimumab at 10 mg/kg (ipi10). E1609 evaluated the safety and efficacy of ipil